HolderBook

MONTE ROSA THERAPEUTICS INC (GLUE)

Institutional ownership reported to the SEC as of Q3 2026, across 22 quarters.

3
Reporting holders
$41.9K
Reported value
0.0%
Calls
0.0%
Puts
-193
Holder change

Calls and puts are the parts of reported value carried in derivative lines rather than shares, and they point in opposite directions: a manager holding calls is positioned for the security, one holding puts against it - or hedging shares they already own, which is why index funds carry so many. Most sites add the two together and report one figure, which averages away the only interesting part.

Holders

Download these holders as CSV

FilerValueShares Their book Held Change
GAMMA Investing LLC$24.1K2,0230.00%4q-4.3%-$1.1K
Paladin Partners, LLC$11.9K1,0000.01%2qHELD
Farther Finance Advisors, LLC$5.8K4890.00%4q+55.2%+$2.1K

Five percent filings

Anyone crossing 5% of a company must say so within days - far sooner than the next quarterly holdings report. A 13D declares an intent to influence the company; a 13G is the passive version. See all activist filings →

FiledFormFiler % of class
2026-08-1413GVestal Point Capital, LPwith 1 co-filers5.4%
2026-08-1413G/AMontanova Capital, LLCwith 2 co-filers4.2%
2026-07-0813G/AT. Rowe Price Associates, Inc.10.5%
2026-07-0613D/ANew Enterprise Associates 17, L.P.with 11 co-filers7.9%

What the insiders did

Open market purchases and sales reported on Form 4 in the last 180 days. Grants, option exercises and shares surrendered to cover tax are left out: they are compensation rather than a decision to buy or sell. Where a broker filled one order in tranches the lines are summed, because it was one decision.

Officers and directors

DateInsiderRoleSideSharesValue
2026-06-24Janku FilipChief Medical OfficerSold30,000$642.7K
2026-06-23Janku FilipChief Medical OfficerSold11,845$239.5K
2026-06-29Manning Anthony M.DirectorSold10,000$231.1K
2026-07-16Warmuth MarkusPresident & CEOSold9,500$220.2K
2026-05-21Manning Anthony M.DirectorSold10,000$180.1K
2026-07-06Townson SharonChief Scientific OfficerSold6,000$139.8K ×2
2026-06-29Janku FilipChief Medical OfficerSold6,000$137.7K
2026-06-30Janku FilipChief Medical OfficerSold5,407$132.5K
2026-05-29Townson SharonChief Scientific OfficerSold6,000$119.2K
2026-06-01Warmuth MarkusPresident & CEOSold5,466$106.3K ×2
2026-05-01Warmuth MarkusPresident & CEOSold5,467$103.4K
2026-07-15Champoux JenniferChief Operating OfficerSold4,351$101.7K

Quarter by quarter

Coverage begins with the quarter ending 2018-12-31. Earlier filings exist only as occasional late amendments, too sparse to describe a market, so they are not shown.

QuarterHoldersValue SharesNewAdded TrimmedOptions
Q3 20263$41.9K3,5120110.0%
Q2 2026196$2.4B98,009,3013081540.9%
Q1 2026191$1.4B87,014,8264682410.4%
Q4 2025161$1.0B64,479,5274753401.1%
Q3 2025128$450.8M60,063,5882534401.3%
Q2 2025118$283.2M62,679,6892549180.2%
Q1 2025107$276.9M59,535,3622221430.2%
Q4 2024108$425.7M60,999,4543434150.6%
Q3 202482$264.8M49,773,3781338120.4%
Q2 202476$172.2M45,914,1551230120.3%
Q1 202469$282.9M40,016,944921200.3%
Q4 202372$231.3M40,205,9391316221.8%
Q3 202373$203.3M42,042,262828141.0%
Q2 202370$272.8M39,746,136931110.2%
Q1 202370$360.4M46,190,126920170.2%
Q4 202267$314.3M41,233,519624150.2%
Q3 202270$328.8M40,254,2231520140.0%
Q2 202257$375.0M38,778,6741218140.0%
Q1 202252$559.9M39,943,48092360.0%
Q4 202153$742.0M36,340,04782390.0%
Q3 202155$759.4M34,892,114276130.0%
Q2 202148$705.1M32,095,19548000.0%